Tyrosine kinase inhibitorFDA-approvedSecond-line
Neratinib
How it works
Blocks the HER2 and epidermal growth factor receptors on cancer cells, inhibiting growth signals and cell division.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Studies show that neratinib can improve progression-free survival and response rates in HER2-positive patients with advanced breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Niraparib and Neratinib in Advanced Solid Tumors and Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing a Combination Therapy for ER-Positive, HER-2 Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Neratinib May Help Reduce Vascular Inflammation and Atherosclerosis | Breast Cancer | animal-study | Treatment with neratinib decreased the plaque burden, reduced the necrotic core size, and mitigated lesional macrophage infiltration. | Source → |
| Neratinib Derivative 7A Shows Promise in Treating Colon Cancer | Colorectal Cancer | lab-study | — | Source → |
| Neratinib Use in Early-Stage Breast Cancer Patients | Breast Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.